Ensysce Biosciences, Inc.
ENSCWDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
This month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
PF614 capsule Phase 3 Est. Readout
Primary completion for PF614 capsule trial (NCT06602271) in Postoperative Pain, Acute
Source| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PF614 capsule | Phase 3 | Postoperative Pain, Acute | - | - |
PF614 | Phase 2 | Acute Pain | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Ensysce Biosciences, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Ensysce Biosciences, Inc.'s (ENSCW) pipeline across Phase 3, Phase 2. Its lead program is PF614 capsule (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Ensysce Biosciences, Inc.'s next FDA catalyst?→
Ensysce Biosciences, Inc.'s (ENSCW) next tracked catalyst is a Phase 3 expected August 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ENSCW biotech catalysts?→
Add ENSCW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ensysce Biosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.